Lupus & antiphospholipid syndrome
Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry—a historical cohort study
Authors' conclusion
The incidence of cancer in patients with SLE in the LUNA cohort did not significantly differ from that in the general population. These findings suggest that CNI treatment in this cohort did not pose a risk factor for cancer development.
Study context
- Population
- Patients with Systemic Lupus Erythematosus (SLE) in the Lupus Registry of Nationwide Institutions (LUNA), Japan625 females (88.8%)
- Participants
- 704 patients
- Exposure
- CNI treatment history vs no CNI treatment history; SLE cohort vs general population
- Outcome
- Incidence of cancer (SIR vs general population) and association between CNI use and cancer risk
Methodological detailsregistry-based (LUNA), standardized incidence ratio, multiple logistic regression, standardization, inverse probability weighting
- Registry-based (LUNA)
- Standardized incidence ratio
- Multiple logistic regression
- Standardization
- Inverse probability weighting
Main finding
As reported in the abstract
Cancer risk by CNI treatment history
CNI vs No CNIEstimate (95% CI)
Multiple logistic regression
OR 1.12(0.42–3.00)
Standardization
RR 1.18(0.47–2.16)
Inverse probability weighting
RR 1.8(0.41–4.66)
Observational data: associations, not effects.
Further findings
Cancer incidence in SLE cohort vs general population (standardized incidence ratio (SIR))
- SIR of cancer in the LUNA cohort
- 1.08 (95% CI 0.74-1.43)
Cancer complications
- Patients with cancer complications
- 38 (5.4%)
- Gynecological malignancies, share of all cancers
- 63.2%
Original publication
Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry—a historical cohort study. Arthritis Res Ther. Published 12 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →